MedTrace Logo

A First-in-Human Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of HMB-003 in Healthy Volunteers

NCT07798505 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2026-09-03

No results posted yet for this study

Summary

The purposes of this clinical study are

1. To see how the new drug (HMB-003) under study is tolerated in healthy volunteers, and if there are any important side effects.
2. To measure the amount of HMB-003 in the body after injection.

Conditions

  • Healthy Adult Participants

Interventions

DRUG

HMB-003

HMB-003 will be administered subcutaneously as a single dose

DRUG

Placebo

Placebo will be administered subcutaneously as a single dose of placebo.

Sponsors & Collaborators

  • Hemab ApS

    lead INDUSTRY

Principal Investigators

  • Medical Director · Hemab

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-08-17
Primary Completion
2027-04-30
Completion
2027-04-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07798505 on ClinicalTrials.gov